Therapeutics
UCB7853
Quick Links
Overview
Name: UCB7853
Therapy Type: Immunotherapy (passive) (timeline)
Target Type: alpha-synuclein
Condition(s): Parkinson's Disease
U.S. FDA Status: Parkinson's Disease (Phase 1)
Company: UCB S.A.
Background
UCB7853 is an α-synuclein antibody. No further information is available on its origin or specificity.
Findings
In December 2020, UCB began a Phase 1 study in healthy men and people with Parkinson's. The study plans to enroll 64 participants in the U.K., and to evaluate single- and multiple-ascending doses of UCB7853 infusion for safety, tolerability, and pharmacokinetics. In June 2021, UCB suspended enrollment for further evaluation, and changed the trial's anticipated completion from September 2022 to April 2023.
For details, see clinicaltrials.gov.
Last Updated: 20 Jul 2021
References
External Citations
Further Reading
No Available Further Reading
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.